The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Background:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treat...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2023 |
| Country: | España |
| Institution: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repository: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p2267 |
| Online Access: | https://i3pt.portalinvestigacion.com/publicaciones/2267 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150526719&doi=10.1177%2f17588359231157641&partnerID=40&md5=7bd57a7cd686fe8d637feb9df728271b |
| Access Level: | Open access |
| Keyword: | gastric cancer HER2-positive nomogram oesophageal cancer survival trastuzumab |
| _version_ | 1878733876715585536 |
|---|---|
| author | Jimenez-Fonseca, P |
| author2 | Foy, V Raby, S Carmona-Bayonas, A Macia-Rivas, L Arrazubi, V Lavin, DC Gil, RHS Custodio, A Cano, JM Montes, AF Mirallas, O Declara, IM Tocino, RV Visa, L Limon, ML Pimentel, P Lago, NM Sauri, T Richard, MM Mangas, M Raga, MG Calvo, A Reguera, P Granja, M Carnicero, AM Perez, CH Cerda, P Gonzalez, LG Navalon, FG Barcia, VP Abad, D Martin, MR Weaver, J Mansoor, W Gallego, J |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| author_browse | Abad, D Arrazubi, V Barcia, VP Calvo, A Cano, JM Carmona-Bayonas, A Carnicero, AM Cerda, P Custodio, A Declara, IM Foy, V Gallego, J Gil, RHS Gonzalez, LG Granja, M Jimenez-Fonseca, P Lago, NM Lavin, DC Limon, ML Macia-Rivas, L Mangas, M Mansoor, W Martin, MR Mirallas, O Montes, AF Navalon, FG Perez, CH Pimentel, P Raby, S Raga, MG Reguera, P Richard, MM Sauri, T Tocino, RV Visa, L Weaver, J |
| author_facet | Jimenez-Fonseca, P Foy, V Raby, S Carmona-Bayonas, A Macia-Rivas, L Arrazubi, V Lavin, DC Gil, RHS Custodio, A Cano, JM Montes, AF Mirallas, O Declara, IM Tocino, RV Visa, L Limon, ML Pimentel, P Lago, NM Sauri, T Richard, MM Mangas, M Raga, MG Calvo, A Reguera, P Granja, M Carnicero, AM Perez, CH Cerda, P Gonzalez, LG Navalon, FG Barcia, VP Abad, D Martin, MR Weaver, J Mansoor, W Gallego, J |
| author_role | author |
| collection | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| description | Background:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Methods:Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). Results:In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. Conclusion:The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_5eb87ea070c43129741b3316741cd54b |
| institution | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| instname_str | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:i3pt.fundanetsuite.com:p2267 |
| publishDate | 2023 |
| publishDateSort | 2023 |
| publisher | SAGE PUBLICATIONS LTD |
| publisherStr | SAGE PUBLICATIONS LTD |
| reponame_str | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| spelling | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy Jimenez-Fonseca, P Foy, V Raby, S Carmona-Bayonas, A Macia-Rivas, L Arrazubi, V Lavin, DC Gil, RHS Custodio, A Cano, JM Montes, AF Mirallas, O Declara, IM Tocino, RV Visa, L Limon, ML Pimentel, P Lago, NM Sauri, T Richard, MM Mangas, M Raga, MG Calvo, A Reguera, P Granja, M Carnicero, AM Perez, CH Cerda, P Gonzalez, LG Navalon, FG Barcia, VP Abad, D Martin, MR Weaver, J Mansoor, W Gallego, J gastric cancer HER2-positive nomogram oesophageal cancer survival trastuzumab Background:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Methods:Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). Results:In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. Conclusion:The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints. SAGE PUBLICATIONS LTD https://i3pt.portalinvestigacion.com/publicaciones/2267 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150526719&doi=10.1177%2f17588359231157641&partnerID=40&md5=7bd57a7cd686fe8d637feb9df728271b |
| spellingShingle | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy Jimenez-Fonseca, P gastric cancer HER2-positive nomogram oesophageal cancer survival trastuzumab |
| status_str | publishedVersion |
| title | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy |
| title_full | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy |
| title_fullStr | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy |
| title_full_unstemmed | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy |
| title_short | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy |
| title_sort | The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy |
| topic | gastric cancer HER2-positive nomogram oesophageal cancer survival trastuzumab |
| topic_facet | gastric cancer HER2-positive nomogram oesophageal cancer survival trastuzumab |
| url | https://i3pt.portalinvestigacion.com/publicaciones/2267 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150526719&doi=10.1177%2f17588359231157641&partnerID=40&md5=7bd57a7cd686fe8d637feb9df728271b |